| Intra-arterial therapies for hepatocellular carcinoma: where do we stand? | |
| | |
MedLine Citation:
|
PMID: 20405328 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE AND DESIGN: Intra-arterial therapies for unresectable hepatocellular carcinoma (HCC) consist of a catheter-based group of treatments where therapeutic and/or embolic agents are intra-arterially directed to target tumors. Here we review these therapies, which may be classified into embolotherapy/chemotherapy-based and radiotherapy-based treatments. Embolotherapy/chemotherapy-based treatments include transcatheter arterial embolization, transarterial chemoembolization, transcatheter arterial chemoeinfusion, and chemoembolization with drug-eluting beads. Radiotherapy-based treatments include radioembolization with yttrium-90 and injection of iodine-131-labeled lipiodol. RESULTS AND CONCLUSION: Interpretation of the results of clinical trials as well as implementation of meta-analyses involving the efficacy of intra-arterial therapies for unresectable HCC has been challenging and difficult to perform. The levels of evidence for treatment recommendations in oncology provide a common framework to understand the current status of intra-arterial therapies for HCC. Here we use an evidence-based approach to critically review and comprehend the current role and future potential of intra-arterial therapies in unresectable HCC. |
| | |
Authors:
|
Eleni Liapi; Jean-Francois H Geschwind |
Related Documents
:
|
3497528 - Intraarterial fibrinolytic therapy for popliteal and tibial artery obstruction: compari... 11354758 - Intra-arterial thrombolysis for acute ischemic stroke. 20659118 - Selective regional perfusion of the bilateral external carotid arteries with pegylated ... 9327688 - Relation between injections before 90-minute angiography and coronary patency: results ... 17531588 - Association of multiple inflammatory markers with carotid intimal medial thickness and ... 16385928 - Retained percutaneous transluminal coronary angioplasty guidewire in coronary circulation. |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-04-20 |
Journal Detail:
|
Title: Annals of surgical oncology Volume: 17 ISSN: 1534-4681 ISO Abbreviation: Ann. Surg. Oncol. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-04-20 Completed Date: 2010-07-29 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9420840 Medline TA: Ann Surg Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 1234-46 Citation Subset: IM |
Affiliation:
|
The Russell H Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, The Johns Hopkins Hospital, Baltimore, MD, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
therapeutic use Carcinoma, Hepatocellular / therapy* Catheter Ablation Embolization, Therapeutic* Humans Infusions, Intra-Arterial* Liver Neoplasms / therapy* Radiotherapy Dosage |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation.
Next Document: Systemic treatment of hepatocellular carcinoma: dawn of a new era?